肥胖指标作为上皮性卵巢癌抗血管生成治疗生存预后生物标志物的测量:NRG Oncology/妇科肿瘤组GOG 218辅助数据分析
基于GOG 218前瞻性III期试验的1538例上皮性卵巢癌患者,分析治疗前CT测量的肥胖指标(BMI、皮下脂肪面积SFA、内脏脂肪面积VFA)与总生存的关系,并评估其是否预测贝伐珠单抗(BEV)疗效。结果显示SFA与总生存无关联(p=0.981),VFA和BMI与死亡风险呈非显著弱相关,肥胖指标均不能预测BEV疗效。
要点
- SFA与总生存无关联(p=0.981),VFA每增加一单位死亡风险非显著增加0.1%(p=0.062)。
- BMI每增加一单位死亡风险非显著增加0.8%(p=0.086),VFA是弱的预后因素。
- 肥胖指标不能预测BEV相比安慰剂的生存获益(SFA p=0.890,VFA p=0.106,BMI p=0.606)。
核心结论
- 肥胖指标(BMI、SFA、VFA)彼此强相关,但不能预测BEV的疗效,VFA是弱的预后因素。
研究设计与样本
- GOG 218前瞻性III期试验的辅助数据分析,分析1538例参与者治疗前CT,其中1019例随机接受化疗+安慰剂→安慰剂或化疗+BEV→BEV。
主要发现
- 调整预后因素后,SFA与总死亡风险无关(p=0.981)。
- VFA每增加一单位,死亡风险非显著增加0.1%(p=0.062)。
- BMI每增加一单位,死亡风险非显著增加0.8%(p=0.086)。
- 比较接受与未接受BEV患者的治疗HR,SFA(p=0.890)和VFA(p=0.106)均无关联。
- BMI不能预测BEV相比安慰剂的更长生存(p=0.606)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Adiposity has been hypothesized to interfere with the activity of bevacizumab (BEV), an anti-angiogenic agent. Measurements of adiposity, BMI, surface fat area (SFA), and visceral fat area (VFA) were investigated as prognostic of oncologic outcomes among patients treated with chemotherapy, with or without BEV, on GOG 218, a prospective phase III trial. METHOD: Pretreatment computed tomography (CT) for 1538 GOG 218 participants were analyzed. Proportional hazards models assessed association between adiposity and overall survival (OS) adjusted for other prognostic factors. The predictive value of adiposity as a function of BEV treatment was assessed in 1019 patients randomized to either chemotherapy (CT) + placebo (P) → P or CT + BEV → BEV. RESULTS: After adjusting for prognostic factors, SFA was not associated with the overall hazard of death (p = 0.981). There was a non-significant 0.1% (p = 0.062) increase in hazard of death associated with a unit increase in VFA. When comparing the treatment HRs for patients who did and did not receive BEV, there was no association with SFA (p = 0.890) or VFA (p = 0.106). A non-significant 0.8% increase in the hazard of death with unit increase in BMI (p = 0.086) was observed. BMI values were not predictive of a longer survival for patients with BEV vs placebo (p = 0.606). CONCLUSION: Measures of adiposity strongly correlated to one another but were not predictive of efficacy for BEV. VFA is a weak prognostic factor.
引用
- Wade KNS, Brady MF, Thai T, et al. Measurements of adiposity as prognostic biomarkers for survival with anti-angiogenic treatment in epithelial ovarian cancer: An NRG Oncology/Gynecologic Oncology Group ancillary data analysis of GOG 218. Gynecol Oncol. 2019. PMID: 31409486. doi:10.1016/j.ygyno.2019.07.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。